Imaging Evaluation of the Therapeutic Response of Breast Cancer Bone Metastasis (EMOS)

Breast cancers are among the cancers that metastasize the most to the skeleton. The appearance of bone metastasis, whether they are initials or during a relapse, is a turning point of the disease, due to the additional morbidity they imply (pain, pathologic fractures, hypercalcaemia, neurological compression, etc.). A specific treatment of these metastasis is often undertaken, usually a chemotherapy or hormone therapy. It is important to evaluate the efficacy of this treatment in order to know whether to continue or change it depending on the response observed. But there is no consensus at this time on paraclinical examinations enabling this monitoring. Also, if some criteria for assessing bone metastasis in imaging and nuclear medicine (MDA, PERCIST, EORTC) have been published in the literature, none is formally validated and evaluation in routine practice remains subjective. The main objective of our study is to determine if the PET-CT and the whole-body MRI are in agreement on the status of bone metastasis (stability, progression, partial response, complete response).

Sex

All

Minimum age

18 Years

Inclusion Criteria:

1. Patient with breast cancer bone metastasis :

   * at the initial diagnosis (group 1).
   * in a metastatic bone relapse (group 2).
   * with a progression of bone metastasis (group 3).
2. Treatment (hormone therapy, chemotherapy) not undertaken (group 1) or prior therapeutic change (group 2 and 3).
3. Patient not opposing the use of its data.

Exclusion Criteria:

1. Claustrophobic patient
2. Patient with an uncontrolled diabetes (fasting glucose \< 1.6 g / l)
3. Patient with a pace-maker or another material incompatible with the MRI 3 Tesla
4. Very algetic patient (Visual Analog Scale (VAS) \> 7)
5. Pregnant or breastfeeding women
6. Patient under 18 or under guardianship
7. Movement disorders (Parkinson disease, etc.) or dementia